Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06017687 · ClinicalTrials.gov registry record · NA

Data Collection and Evaluation of OptiBP Under Investigational Use

A NA study of General Population, sponsored by Biospectal.

Recruiting
Registry status
NA
Development phase
500,000
Enrollment target
1
Study location

NCT06017687: Recruiting NA study of General Population, sponsored by Biospectal.

NCT06017687 is a NA study of General Population that is actively recruiting participants, run by Biospectal. The registered enrollment target is 500,000 participants, above the 1,395-participant average among 58,714 other NA trials with a reported enrollment target (35742% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06017687, a NA study of General Population, is actively recruiting participants, sponsored by Biospectal.

RECRUITING
Registry status
NA
Development phase
500,000 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to collect data to develop and evaluate the use of state-of-the-art machine learning approaches within a mobile phone application for the estimation of blood pressure.

Primary Outcome

To collect data to train a machine-learning based solution for estimating blood pressure. Participants will simultaneously acquire blood pressure measurements through a cuff-based, automatic, over-the-counter blood pressure monitor at the upper arm, while recording an optical signal through the camera of a smartphone on the tip of the index of the opposite arm. The performance of the machine learning model will be assessed by calculating the mean and standard deviation of the error of blood pres

Conditions Studied

Interventions

  • DEVICE OptiBP Study app

Study Locations (1)

California

  • Decentralized Trial - Truckee

Trial Details

FieldValue
Enrollment Target 500,000 participants
Start Date 2023-09-28
Est. Completion 2026-09
Phase NA
Biospectal

1 total trials

What NCT06017687 shows while recruiting

NCT06017687 is an interventional study that assigns participants to a tested intervention. Its 500,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,395-participant average among 58,714 other NA trials with a reported enrollment target (35742% higher).

The record links to 1 condition, with General Population appearing as the primary indexed condition, and to 1 intervention - of which OptiBP Study app is the first listed.

NCT06017687 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06017687 about?

NCT06017687 is a clinical study titled "Data Collection and Evaluation of OptiBP Under Investigational Use". The purpose of this study is to collect data to develop and evaluate the use of state-of-the-art machine learning approaches within a mobile phone application for the estimation of blood pressure.

What is the current status of trial NCT06017687?

This trial is currently recruiting. It is a NA study. The enrollment target is 500,000 participants. The study started on 2023-09-28. Estimated completion is 2026-09.

What conditions does trial NCT06017687 study?

This clinical trial studies the following conditions: General Population.

What interventions are being tested in trial NCT06017687?

The interventions under investigation include: OptiBP Study app (DEVICE).

Who is sponsoring clinical trial NCT06017687?

This trial is sponsored by Biospectal, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06017687 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for General Population

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06017687's enrollment target sits among peer trials

500,000 1st of 2000 higher than 2,000 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05065060 · 500,000 participants

    Parkinson Progression Marker Initiative Online (PPMI Online)

  • NCT06342375 · 425,000 participants · NA

    Enrollment Barriers, Procedural Denials, and Loss of Medicaid Coverage

  • NCT06934239 · 400,000 participants · Phase 4

    A Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients

  • NCT05668637 · 318,542 participants

    Evaluation and Further Development of an Artificial Intelligence-based Algorithm for Clinical Decision Support

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06017687, the US trial registry maintained by the National Library of Medicine. NCT06017687 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.